Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 38
Filter
2.
Front Immunol ; 14: 1122409, 2023.
Article in English | MEDLINE | ID: mdl-36891297

ABSTRACT

Mast cells (MCs) are innate immune cells with a versatile set of functionalities, enabling them to orchestrate immune responses in various ways. Aside from their known role in allergy, they also partake in both allograft tolerance and rejection through interaction with regulatory T cells, effector T cells, B cells and degranulation of cytokines and other mediators. MC mediators have both pro- and anti-inflammatory actions, but overall lean towards pro-fibrotic pathways. Paradoxically, they are also seen as having potential protective effects in tissue remodeling post-injury. This manuscript elaborates on current knowledge of the functional diversity of mast cells in kidney transplants, combining theory and practice into a MC model stipulating both protective and harmful capabilities in the kidney transplant setting.


Subject(s)
Hypersensitivity , Kidney Transplantation , Humans , Mast Cells , Cytokines/metabolism , T-Lymphocytes, Regulatory/metabolism
3.
Am J Transplant ; 18(2): 293-307, 2018 02.
Article in English | MEDLINE | ID: mdl-29243394

ABSTRACT

The kidney sessions of the 2017 Banff Conference focused on 2 areas: clinical implications of inflammation in areas of interstitial fibrosis and tubular atrophy (i-IFTA) and its relationship to T cell-mediated rejection (TCMR), and the continued evolution of molecular diagnostics, particularly in the diagnosis of antibody-mediated rejection (ABMR). In confirmation of previous studies, it was independently demonstrated by 2 groups that i-IFTA is associated with reduced graft survival. Furthermore, these groups presented that i-IFTA, particularly when involving >25% of sclerotic cortex in association with tubulitis, is often a sequela of acute TCMR in association with underimmunosuppression. The classification was thus revised to include moderate i-IFTA plus moderate or severe tubulitis as diagnostic of chronic active TCMR. Other studies demonstrated that certain molecular classifiers improve diagnosis of ABMR beyond what is possible with histology, C4d, and detection of donor-specific antibodies (DSAs) and that both C4d and validated molecular assays can serve as potential alternatives and/or complements to DSAs in the diagnosis of ABMR. The Banff ABMR criteria are thus updated to include these alternatives. Finally, the present report paves the way for the Banff scheme to be part of an integrative approach for defining surrogate endpoints in next-generation clinical trials.


Subject(s)
Graft Rejection/diagnosis , High-Throughput Nucleotide Sequencing/methods , Inflammation/diagnosis , Isoantibodies/immunology , Kidney Transplantation/adverse effects , Postoperative Complications , T-Lymphocytes/immunology , Graft Rejection/etiology , Graft Rejection/pathology , Humans , Inflammation/etiology , Inflammation/pathology , Prognosis , Research Report
4.
Am J Transplant ; 17(11): 2851-2862, 2017 Nov.
Article in English | MEDLINE | ID: mdl-28449409

ABSTRACT

The authors conducted a prospective trial to assess the feasibility of real time central molecular assessment of kidney transplant biopsy samples from 10 North American or European centers. Biopsy samples taken 1 day to 34 years posttransplantation were stabilized in RNAlater, sent via courier overnight at ambient temperature to the central laboratory, and processed (29 h workflow) using microarrays to assess T cell- and antibody-mediated rejection (TCMR and ABMR, respectively). Of 538 biopsy samples submitted, 519 (96%) were sufficient for microarray analysis (average length, 3 mm). Automated reports were generated without knowledge of histology and HLA antibody, with diagnoses assigned based on Molecular Microscope Diagnostic System (MMDx) classifier algorithms and signed out by one observer. Agreement between MMDx and histology (balanced accuracy) was 77% for TCMR, 77% for ABMR, and 76% for no rejection. A classification tree derived to provide automated sign-outs predicted the observer sign-outs with >90% accuracy. In 451 biopsy samples where feedback was obtained, clinicians indicated that MMDx more frequently agreed with clinical judgment (87%) than did histology (80%) (p = 0.0042). In 81% of feedback forms, clinicians reported that MMDx increased confidence in management compared with conventional assessment alone. The authors conclude that real time central molecular assessment is feasible and offers a useful new dimension in biopsy interpretation. ClinicalTrials.gov NCT#01299168.


Subject(s)
Biomarkers/metabolism , Gene Expression Profiling , Graft Rejection/diagnosis , Kidney Failure, Chronic/surgery , Kidney Transplantation/adverse effects , Adult , Aged , Aged, 80 and over , Biopsy , Female , Follow-Up Studies , Glomerular Filtration Rate , Graft Rejection/etiology , Graft Rejection/metabolism , Graft Survival , Humans , Kidney Function Tests , Male , Middle Aged , Prognosis , Prospective Studies , Risk Factors , Young Adult
5.
Am J Transplant ; 17(2): 496-505, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27401781

ABSTRACT

Precise diagnosis of antibody-mediated rejection (AMR) in cardiac allograft endomyocardial biopsies (EMBs) remains challenging. This study assessed molecular diagnostics in human EMBs with AMR. A set of 34 endothelial, natural killer cell and inflammatory genes was quantified in 106 formalin-fixed, paraffin-embedded EMBs classified according to 2013 International Society for Heart and Lung Transplantation (ISHLT) criteria. The gene set expression was compared between ISHLT diagnoses and correlated with donor-specific antibody (DSA), endothelial injury by electron microscopy (EM) and prognosis. Findings were validated in an independent set of 57 EMBs. In the training set (n = 106), AMR cases (n = 70) showed higher gene set expression than acute cellular rejection (ACR; n = 21, p < 0.001) and controls (n = 15, p < 0.0001). Anti-HLA DSA positivity was associated with higher gene set expression (p = 0.01). Endothelial injury by electron microscopy strongly correlated with gene set expression, specifically in AMR cases (r = 0.62, p = 0.002). Receiver operating characteristic curve analysis for diagnosing AMR showed greater accuracy with gene set expression (area under the curve [AUC] = 79.88) than with DSA (AUC = 70.47) and C4d (AUC = 70.71). In AMR patients (n = 17) with sequential biopsies, increasing gene set expression was associated with inferior prognosis (p = 0.034). These findings were confirmed in the validation set. In conclusion, biopsy-based molecular assessment of antibody-mediated microcirculation injury has the potential to improve diagnosis of AMR in human cardiac transplants.


Subject(s)
Biomarkers/analysis , Formaldehyde/chemistry , Graft Rejection/diagnosis , Heart Transplantation/adverse effects , Isoantibodies/immunology , Microcirculation/genetics , Tissue Donors , Adult , Allografts , Biopsy , Female , Follow-Up Studies , Gene Expression Profiling , Graft Rejection/etiology , Graft Survival , Heart Failure/surgery , Humans , Killer Cells, Natural/immunology , Killer Cells, Natural/metabolism , Male , Middle Aged , Prognosis , Retrospective Studies , Risk Factors
6.
Am J Transplant ; 17(1): 42-53, 2017 01.
Article in English | MEDLINE | ID: mdl-27862968

ABSTRACT

The 13th Banff Conference on Allograft Pathology was held in Vancouver, British Columbia, Canada from October 5 to 10, 2015. The cardiac session was devoted to current diagnostic issues in heart transplantation with a focus on antibody-mediated rejection (AMR) and small vessel arteriopathy. Specific topics included the strengths and limitations of the current rejection grading system, the central role of microvascular injury in AMR and approaches to semiquantitative assessment of histopathologic and immunophenotypic indicators, the role of AMR in the development of cardiac allograft vasculopathy, the important role of serologic antibody detection in the management of transplant recipients, and the potential application of new molecular approaches to the elucidation of the pathophysiology of AMR and potential for improving the current diagnostic system. Herein we summarize the key points from the presentations, the comprehensive, open and wide-ranging multidisciplinary discussion that was generated, and considerations for future endeavors.


Subject(s)
Graft Rejection/pathology , Isoantibodies/immunology , Organ Transplantation/adverse effects , Practice Guidelines as Topic/standards , Graft Rejection/etiology , Humans , Isoantibodies/blood , Research Report , Transplantation, Homologous
7.
Am J Transplant ; 16(1): 111-20, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26588356

ABSTRACT

In heart transplantation, there is a lack of robust evidence of the specific causes of late allograft failure. We hypothesized that a substantial fraction of failing heart allografts may be associated with antibody-mediated injury and immune-mediated coronary arteriosclerosis. We included all patients undergoing a retransplantation for late terminal heart allograft failure in three referral centers. We performed an integrative strategy of heart allograft phenotyping by assessing the heart vascular tree including histopathology and immunohistochemistry together with circulating donor-specific antibodies. The main analysis included 40 explanted heart allografts patients and 402 endomyocardial biopsies performed before allograft loss. Overall, antibody-mediated rejection was observed in 19 (47.5%) failing heart allografts including 16 patients (40%) in whom unrecognized previous episodes of subclinical antibody-mediated rejection occurred 4.5 ± 3.5 years before allograft loss. Explanted allografts with evidence of antibody-mediated rejection demonstrated higher endothelitis and microvascular inflammation scores (0.89 ± 0.26 and 2.25 ± 0.28, respectively) compared with explanted allografts without antibody-mediated rejection (0.42 ± 0.11 and 0.36 ± 0.09, p = 0.046 and p < 0.0001, respectively). Antibody-mediated injury was observed in 62.1% of failing allografts with pure coronary arteriosclerosis and mixed (arteriosclerosis and atherosclerosis) pattern, while it was not observed in patients with pure coronary atherosclerosis (p = 0.0076). We demonstrate that antibody-mediated rejection is operating in a substantial fraction of failing heart allografts and is associated with severe coronary arteriosclerosis. Unrecognized subclinical antibody-mediated rejection episodes may be observed years before allograft failure.


Subject(s)
Coronary Artery Disease/pathology , Graft Rejection/pathology , Heart Failure/surgery , Heart Transplantation/adverse effects , Isoantibodies/adverse effects , Adult , Allografts , Coronary Artery Disease/etiology , Female , Graft Rejection/etiology , Humans , Isoantibodies/blood , Male , Reoperation
8.
Am J Transplant ; 15(2): 526-34, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25612500

ABSTRACT

This multicenter case-controlled pilot study evaluated myocardial inflammatory burden (IB) and phenotype in endomyocardial biopsies (EMBs) with and without pathologic antibody-mediated rejection (pAMR). Sixty-five EMBs from five European heart transplant centers were centrally reviewed as positive (grade 2, n = 28), suspicious (grade 1, n = 7) or negative (n = 30) for pAMR. Absolute counts of total, intravascular (IV) and extravascular (EV) immunophenotyped mononuclear cells were correlated with pAMR grade, capillary C4d deposition, donor specific antibody (DSA) status and acute cellular rejection (ACR). In pAMR+ biopsies, equivalent number of IV CD3+ T lymphocytes (23 ± 4/0.225 mm(2) ) and CD68+ macrophages (21 ± 4/0.225 mm(2) ) were seen. IB and cell phenotype correlated with pAMR grade, C4d positivity and DSA positivity (p < 0.0001). High numbers of IV T lymphocytes were associated with low grade ACR (p = 0.002). In late-occurring AMR EV plasma cells occurring in 34% of pAMR+ EMBs were associated with higher IB. The IB in AMR correlated with pAMR+, C4d positivity and DSA positivity. In pAMR+ equivalent numbers of IV T lymphocytes and macrophages were found. The presence of plasma cells was associated with a higher IB and occurrence of pAMR late after transplantation.


Subject(s)
Antibodies/immunology , Graft Rejection/immunology , Graft Rejection/pathology , Heart Transplantation , Inflammation/pathology , Myocarditis/pathology , Phenotype , Adult , Biopsy , Capillaries/metabolism , Capillaries/pathology , Case-Control Studies , Complement C4b/metabolism , Europe , Female , Graft Rejection/epidemiology , Humans , Incidence , Male , Middle Aged , Peptide Fragments/metabolism , Pilot Projects , Retrospective Studies , Tissue Donors
9.
Am J Transplant ; 14(11): 2623-32, 2014 Nov.
Article in English | MEDLINE | ID: mdl-25307253

ABSTRACT

Adenine phosphoribosyltransferase (APRT) deficiency is a rare autosomal recessive enzyme defect of purine metabolism that usually manifests as 2,8-dihydroxyadenine (2,8-DHA) nephrolithiasis and more rarely chronic kidney disease. The disease is most often misdiagnosed and can recur in the renal allograft. We analyzed nine patients with recurrent 2,8-DHA crystalline nephropathy, in all of whom the diagnosis had been missed prior to renal transplantation. The diagnosis was established at a median of 5 (range 1.5-312) weeks following the transplant procedure. Patients had delayed graft function (n=2), acute-on-chronic (n=5) or acute (n=1) allograft dysfunction, whereas one patient had normal graft function at the time of diagnosis. Analysis of allograft biopsies showed birefringent 2,8-DHA crystals in renal tubular lumens, within tubular epithelial cells and interstitium. Fourier transformed infrared microscopy confirmed the diagnosis in all cases, which was further supported by 2,8-DHA crystalluria, undetectable erythrocyte APRT enzyme activity, and genetic testing. With allopurinol therapy, the allograft function improved (n=7), remained stable (n=1) or worsened (n=1). At last follow-up, two patients had experienced allograft loss and five had persistent chronic allograft dysfunction. 2,8-DHA nephropathy is a rare but underdiagnosed and preventable disorder that can recur in the renal allograft and may lead to allograft loss.


Subject(s)
Adenine Phosphoribosyltransferase/deficiency , Graft Rejection , Kidney Transplantation , Metabolism, Inborn Errors/etiology , Urolithiasis/etiology , Adult , Aged , Female , Humans , Male , Metabolism, Inborn Errors/physiopathology , Middle Aged , Recurrence , Urolithiasis/physiopathology
10.
Am J Transplant ; 13(10): 2567-76, 2013 10.
Article in English | MEDLINE | ID: mdl-23919486

ABSTRACT

The angiotensin II type 1 receptor (AT1R) is an emerging target of functional non-HLA antibodies (Ab). We examined the potential of determining the degree of presensitization against AT1R as a risk factor for graft survival and acute rejection (AR). The study included 599 kidney recipients between 1998 and 2007. Serum samples were analyzed in a blinded fashion for anti-AT1R antibodies (AT1R-Abs) using a quantitative solid-phase assay. A threshold of AT1R-Ab levels was statistically determined at 10 U based on the time to graft failure. An extended Cox model determined risk factors for occurrence of graft failure and a first AR episode. AT1R-Abs >10 U were detected in 283 patients (47.2%) before transplantation. Patients who had a level of AT1R-Abs >10 U had a 2.6-fold higher risk of graft failure from 3 years posttransplantation onwards (p = 0.0005) and a 1.9-fold higher risk of experiencing an AR episode within the first 4 months of transplantation (p = 0.0393). Antibody-mediated rejection (AMR) accounted for 1/3 of AR, whereby 71.4% of them were associated with >10 U of pretransplant AT1R-Abs. Pretransplant anti-AT1R-Abs are an independent risk factor for long-term graft loss in association with a higher risk of early AR episodes.


Subject(s)
Autoantibodies/blood , Graft Rejection/immunology , Graft Survival/immunology , Kidney Transplantation , Receptor, Angiotensin, Type 1/immunology , Transplantation Immunology , Acute Disease , Adult , Autoantibodies/immunology , Enzyme-Linked Immunosorbent Assay , Female , Follow-Up Studies , Graft Rejection/blood , Graft Rejection/diagnosis , HLA Antigens/immunology , Humans , Kidney Diseases/blood , Kidney Diseases/surgery , Male , Middle Aged , Preoperative Care , Prospective Studies , Transplantation, Homologous
11.
J Thromb Haemost ; 10(1): 38-48, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22066680

ABSTRACT

BACKGROUND: Fucoidan, an antithrombotic polysaccharide, can induce endothelial colony-forming cells (ECFC) to adopt an angiogenic phenotype in vitro. OBJECTIVES: We evaluated the effect of fucoidan on vasculogenesis induced by ECFC in vivo. METHODS: We used a murine hindlimb ischemia model to probe the synergic role of fucoidan-treatment and ECFC infusion during tissue repair. RESULTS: We found that exposure of ECFC to fucoidan prior to their intravenous injection improved residual muscle blood flow and increased collateral vessel formation. Necrosis of ischemic tissue was significantly reduced on day 14, to 12.1% of the gastronecmius cross-sectional surface area compared with 40.1% in animals injected with untreated-ECFC. ECFC stimulation with fucoidan caused a rapid increase in cell adhesion to activated endothelium in flow conditions, and enhanced transendothelial extravasation. Fucoidan-stimulated ECFC were resistant to shear stresses of up to 21 dyn cm(-2). Direct binding assays showed strong interaction of fucoidan with displaceable binding sites on the ECFC membrane. Bolus intramuscular administration of fucoidan 1 day after surgery reduces rhabdomyolysis. Mice injected with fucoidan (15 mg kg(-1)) had significantly lower mean serum creatine phosphokinase (CPK) activity than control animals. This CPK reduction was correlated with muscle preservation against necrosis (P < 0.001). CONCLUSIONS: Fucoidan greatly increases ECFC-mediated angiogenesis in vivo. Its angiogenic effect would be due in part to its transportation to the ischemic site and its release after displacement by proteoglycans present in the extracellular matrix. The use of ECFC and fucoidan together, will be an efficient angiogenesis strategy to provide therapeutic neovascularization.


Subject(s)
Endothelial Cells/transplantation , Ischemia/drug therapy , Neovascularization, Physiologic/drug effects , Polysaccharides/therapeutic use , Animals , Anticoagulants , Endothelial Cells/drug effects , Mice , Muscles/blood supply , Polysaccharides/administration & dosage , Regional Blood Flow/drug effects , Stem Cell Transplantation , Stem Cells
12.
J Cell Biochem ; 113(6): 1820-32, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22134986

ABSTRACT

Recent findings indicated that the SMILE gene may be involved in kidney graft operational tolerance in human. This gene was found to be up-regulated in blood from patients with a well functioning kidney transplant in the absence of immunosuppression compared to other transplanted recipients with clinically different status. A microarray study of SMILE knock-down and phorbol 12-myristate 13-acetate (PMA) activation in HeLa cells was herein compared to our earlier analysis based on microarray data of kidney allograft tolerance and rejection in humans and in a rat model of allograft transplantation to determine possible new genes and gene networks involved in kidney transplantation. The nearest neighbors at the intersection of the SMILE knock-down network with the human tolerance/rejection networks are shown to be NPHS1 and ARRB2, the former (Nephrin) being involved in kidney podocyte function, and the decrease of the latter (Arrestin ß2) being recently shown to be involved in monocyte activation during acute kidney allograft rejection in rat. Moreover, another one of the neighbors at the intersection of SMILE network and tolerance/rejection networks is XBP-1, that we report previously to be increased, at a transcript level, after ER stress in SMILE silenced cells. Finally, in this study, we also show that topological properties (both local and global) of joint SMILE knock-down network-tolerance/rejection networks and joint PMA activation network-tolerance/rejection networks in rat and human are essentially different, likely due to the inherent nature of the gene SMILE and the mitogen PMA, that do not act the same way on genes and do not interfere the same way on networks. We also show that interestingly SMILE networks contain more feed-forward loop (FFL) motifs and thus SMILE calls for a more fine-tuned genetic regulation.


Subject(s)
Basic-Leucine Zipper Transcription Factors/genetics , Gene Regulatory Networks , Kidney Transplantation , Transplantation Tolerance/genetics , Animals , Arrestins/genetics , Basic-Leucine Zipper Transcription Factors/biosynthesis , DNA-Binding Proteins/biosynthesis , DNA-Binding Proteins/genetics , Gene Expression Regulation , Graft Rejection/genetics , HeLa Cells , Humans , Kidney/metabolism , Membrane Proteins/genetics , Oligonucleotide Array Sequence Analysis , RNA Interference , RNA, Small Interfering , Rats , Regulatory Factor X Transcription Factors , Tetradecanoylphorbol Acetate/pharmacology , Transcription Factors/biosynthesis , Transcription Factors/genetics , X-Box Binding Protein 1 , beta-Arrestin 2 , beta-Arrestins
13.
Am J Transplant ; 11(7): 1478-87, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21668629

ABSTRACT

In heart transplants, the significance of very late rejection (after 7 years post-transplant, VLR) detected by routine endomyocardial biopsies (EMB) remains uncertain. Here, we assessed the prevalence, histopathological and immunological phenotype, and outcome of VLR in clinically stable patients. Between 1985 and 2009, 10 662 protocol EMB were performed at our institution in 398 consecutive heart transplants recipients. Among the 196 patients with >7-year follow-up, 20 (10.2%) presented subclinical ≥3A/2R-ISHLT rejection. The VLR group was compared to a matched control group of patients without rejection. All biopsies were stained for C4d/C3d/CD68 with sera screened for the presence of donor-specific antibodies (DSAs). In addition to cellular infiltrates with myocyte damage, 60% of VLR patients had evidence of intravascular macrophages. C4d and/or C3d-capillary deposition was found in 55% VLR EMB. All cases of VLR associated with microcirculation injury had DSAs (mean DSA(max) -MFI = 1751 ± 583). This entity was absent from the control group (p < 0.0001). Finally, after a similar follow-up postreference EMB of 6.4 ± 1 years, the mean of CAV grade was 0.76 ± 0.18 in the control group compared to 2.06 ± 0.26 in the VLR group respectively, p = 0.001). There was no difference in patient survival between study and control groups. In conclusion, VLR is frequently associated with complement-cascade activation, microvascular injury and DSA, suggesting an antibody-mediated process. VLR is associated with a dramatic progression to severe CAV in long-term follow-up.


Subject(s)
Graft Rejection/immunology , Graft Rejection/pathology , Heart Transplantation/pathology , Adult , Antibodies/immunology , Complement Activation , Female , Follow-Up Studies , Heart Transplantation/immunology , Heart Transplantation/mortality , Humans , Male , Middle Aged , Retrospective Studies , Tissue Donors
14.
J Am Soc Nephrol ; 22(5): 975-83, 2011 May.
Article in English | MEDLINE | ID: mdl-21493773

ABSTRACT

In biopsies of renal allografts, arteriosclerosis is often more severe than expected based on the age of the donor, even without a history of rejection vasculitis. To determine whether preformed donor-specific antibodies (DSAs) may contribute to the severity of arteriosclerosis, we examined protocol biopsies from patients with (n=40) or without (n=59) DSA after excluding those with any evidence of vasculitis. Among DSA-positive patients, arteriosclerosis significantly progressed between month 3 and month 12 after transplant (mean Banff cv score 0.65 ± 0.11 to 1.12 ± 0.10, P=0.014); in contrast, among DSA-negative patients, we did not detect a statistically significant progression during the same timeframe (mean Banff cv score 0.65 ± 0.11 to 0.81 ± 0.10, P=not significant). Available biopsies at later time points supported a rate of progression of arteriosclerosis in DSA-negative patients that was approximately one third that in DSA-positive patients. Accelerated arteriosclerosis was significantly associated with peritubular capillary leukocytic infiltration, glomerulitis, subclinical antibody-mediated rejection, and interstitial inflammation. In conclusion, these data support the hypothesis that donor-specific antibodies dramatically accelerate post-transplant progression of arteriosclerosis.


Subject(s)
Antibodies/immunology , Arteriosclerosis/etiology , Kidney Transplantation/adverse effects , Kidney Transplantation/immunology , Tissue Donors , Adolescent , Adult , Aged , Aged, 80 and over , Biopsy , Humans , Kidney/pathology , Kidney/physiopathology , Middle Aged , Transplantation, Homologous
15.
Diabetes Metab ; 37(3): 245-51, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21257329

ABSTRACT

AIM: Recent evidence shows that adult metabolic disease may originate from an adverse fetal environment that can alter organ development and function in postnatal life. This study aimed to analyze the effect of exposure in utero to maternal diabetes on the development of the metabolic syndrome in the offspring. METHODS: Pregnant rats were made diabetic (blood glucose was 20mM) with a single streptozotocin injection on day 0 of gestation. Offspring from diabetic mothers (DMO) and control mothers (CMO) were followed from birth to 12 months of age. In these animals, metabolic parameters, such as glucose tolerance, insulin sensitivity and plasma lipid levels, as well as pancreatic insulin and morphology were studied. RESULTS: Compared with controls, DMO offspring had normal birth weights, but impaired postnatal growth that persisted throughout life. Metabolic tests revealed that DMO offspring also showed impaired glucose tolerance at six months associated with decreased insulin sensitivity and low insulin secretion. In older animals (12 months old), this phenotype persisted, but to a lesser extent. The DMO offspring also presented with high blood pressure and decreased levels of fasting plasma triglycerides, but normal plasma NEFA, and HDL and total cholesterol. CONCLUSION: Altogether, these results show that our model of exposure in utero to maternal diabetes led to normal birth weights, and induced transient glucose intolerance and increased blood pressure with no major effects on lipid metabolism. It also suggests that a hyperglycaemic fetal environment may be able to 'programme' hypertension and glucose intolerance, but not alter lipid metabolism.


Subject(s)
Diabetes, Gestational/metabolism , Glucose Intolerance/etiology , Hypertension/etiology , Prenatal Exposure Delayed Effects , Analysis of Variance , Animals , Animals, Newborn , Area Under Curve , Diabetes Mellitus, Experimental/etiology , Diabetes Mellitus, Experimental/metabolism , Female , Glucose/metabolism , Hyperglycemia/etiology , Hyperglycemia/metabolism , Hypertension/metabolism , Insulin/metabolism , Lipid Metabolism , Metabolic Syndrome/etiology , Metabolic Syndrome/metabolism , Pregnancy , Rats , Rats, Sprague-Dawley , Statistics, Nonparametric , Weight Gain
16.
Am J Transplant ; 9(11): 2561-70, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19775320

ABSTRACT

This study describes clinical relevance of subclinical antibody-mediated rejection (SAMR) in a cohort of 54 DSA-positive kidney transplant recipients receiving a deceased donor. In 3 months screening biopsies, 31.1% of patients met the criteria of SAMR. A total of 48.9% had an incomplete form of SAMR (g+/ptc+/C4d-negative) whereas 20% had no humoral lesions. Patients with SAMR at 3 months had at 1 year: a higher C4d score, ptc score, and arteriosclerosis score, higher rate of IFTA (100% vs. 33.3%, p < 0.01) and a higher rate of transplant glomerulopathy (43% vs. 0%, p = 0.02) compared to patients without 3-month SAMR. Patients with SAMR at 3 months exhibited at 1 year a higher class II MFImax-DSA and a lower mGFR compared to patients without SAMR (39.2 +/- 13.9 vs. 61.9 +/- 19.2 mL/min/1.73 m(2) respectively, p < 0.01). The group of patients with C4d-negative SAMR at 3 months developed more ptc and IFTA lesions, and lower GFR at 1 year in comparison to biopsies without humoral lesions. SAMR is a frequent entity in KTR with preexisting DSAs and promotes subsequent GFR impairment and development of chronic AMR. C4d-negative SAMR patients displayed an intermediate course between the no-SAMR group and the C4d+ SAMR group. Screening biopsies may be useful to recognize patients more likely to develop SAMR.


Subject(s)
Antibody Specificity , Graft Rejection/immunology , Isoantibodies/immunology , Kidney Transplantation/immunology , Kidney/immunology , Acute Disease , Adult , Biopsy , Complement C4b/immunology , Glomerular Filtration Rate/immunology , Graft Rejection/mortality , Graft Rejection/pathology , Graft Survival/immunology , HLA Antigens/genetics , Humans , Kaplan-Meier Estimate , Kidney/pathology , Kidney Transplantation/mortality , Middle Aged , Peptide Fragments/immunology , Proteinuria/immunology , Proteinuria/mortality , Proteinuria/pathology , Risk Factors , Tissue Donors
17.
Am J Transplant ; 8(6): 1345-8, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18522550

ABSTRACT

Fabry disease (FD) is an X-linked genetic disease, resulting from the deficiency of alpha-galactosidase A, a lysosomal enzyme responsible for the cleavage of glycosphingolipids. In absence of enzyme replacement therapy (ERT), globotriaosylceramide (Gb3) accumulates in tissue, leading to progressive organ damage with severe renal, cardiac and central nervous system complications. We herein describe the first case of successful combined and simultaneous heart and kidney transplantation in a young male patient with FD complicated by end-stage renal disease and severe heart failure not responding to late-onset ERT. Combined heart and kidney transplantation can be recommended for Fabry patients with end-stage renal disease and overt hypertrophic cardiomyopathy, severe ischemic or valvular heart disease.


Subject(s)
Fabry Disease/complications , Heart Failure/surgery , Kidney Failure, Chronic/surgery , Adult , Enzyme Therapy , Heart Failure/drug therapy , Heart Failure/etiology , Heart Transplantation , Humans , Kidney Failure, Chronic/drug therapy , Kidney Failure, Chronic/etiology , Kidney Transplantation , Male , alpha-Galactosidase/therapeutic use
19.
Clin Exp Med ; 5(4): 135-40, 2005 Dec.
Article in English | MEDLINE | ID: mdl-16362793

ABSTRACT

Intravenous immunoglobulin (IVIg) has been used in the treatment of primary and secondary antibody deficiencies for over two decades. Since the early 1980s, the therapeutic efficacy of IVIg has been established in idiopathic thrombocytopenic purpura, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, dermatomyositis and Kawasaki syndrome, and the prevention of graft versus host disease in recipients of allogeneic bone marrow transplants. Its use has also been reported in a large number of other autoimmune and systemic inflammatory conditions. In this review, we discuss the mechanisms by which IVIg exerts immunomodulatory effects in immune pathologies.


Subject(s)
Autoimmune Diseases/drug therapy , Immunoglobulins, Intravenous/therapeutic use , Inflammation/drug therapy , Antigen-Presenting Cells/immunology , Autoantibodies/immunology , B-Lymphocytes/immunology , Complement System Proteins/physiology , Cytokines/biosynthesis , Dendritic Cells/immunology , Humans , Inflammation/immunology , Myelin Sheath , Neutralization Tests , T-Lymphocytes/immunology
20.
Cell Tissue Res ; 314(3): 367-79, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14523643

ABSTRACT

Exposure to hyperglycemia in utero impairs rat nephrogenesis. The effect of maternal diabetes on insulin-like growth factors and their receptors in the fetal kidney is associated with an increase in both mRNA and protein of the insulin-like growth factor II/mannose 6-phosphate receptor. However, this receptor has never been localized in the fetal kidney. The spatial and temporal distribution of the three insulin-like growth factor receptors (insulin-like growth factor I receptor, insulin-like growth factor II/mannose 6-phosphate receptor and insulin receptor) in rat metanephros during both normal and streptozotocin-induced diabetic renal development was investigated using in situ hybridization and immunohistochemistry. All receptors were found in the fetal kidney from the start of nephrogenesis. Insulin-like growth factor I receptor expression was ubiquitous and continuously present during metanephric development. Insulin receptor expression was developmentally regulated during kidney maturation with an enhanced expression in proximal tubules at the late stages of development. Insulin-like growth factor II/mannose 6-phosphate receptor expression was ubiquitous in the early stages of development and was dramatically decreased at the late stages of normal kidney development. Insulin receptor and insulin-like growth factor I receptor expressions were unchanged in diabetic metanephroi. Although the spatial expression of insulin-like growth factor II/mannose 6-phosphate receptor was unaffected by hyperglycemia, its expression was not downregulated in the mesenchyme of the nephrogenic zone of diabetic fetuses on gestational day 20. This study suggests a crucial role of insulin-like growth factor II/mannose 6-phosphate receptor in the pathogenesis of the impaired nephrogenesis in fetuses of diabetic mothers.


Subject(s)
Diabetes Mellitus, Experimental/complications , Kidney/abnormalities , Kidney/metabolism , Organogenesis/physiology , Pregnancy in Diabetics/complications , Receptor, IGF Type 1/metabolism , Receptor, IGF Type 2/metabolism , Receptor, Insulin/metabolism , Animals , Disease Models, Animal , Down-Regulation/physiology , Female , Hyperglycemia/complications , Immunohistochemistry , Kidney/physiopathology , Pregnancy , RNA, Messenger/metabolism , Rats , Rats, Sprague-Dawley , Receptor, IGF Type 1/genetics , Receptor, IGF Type 2/genetics , Receptor, Insulin/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...